Project Management


Job Description


Position: Project Management


Report to: R&D Head


Location: Beijing


Language: Chinese & English



     Manage all CMC project plans and timeline, including research pre-clinic and clinic stage CMC projects, and working with financing department to manage RD budget

     Worked closely with internal and external project team to make sure all project on time smoothly by coordinating resources, regular tracking, weekly reporting to senior management team etc.

     Manage risks and changes in the project, and timely coordinate related resources to solve the problems of the project;

     Responsible for the key millstone review of the project and documentation review and filing;

     Coordinate the internal and external partners of the project, assist the project team to select external suppliers, and ensure the participation of all functional departments within the company in the project;

     Other tasks that may assigned by Supervisor or CEO



❒  PH D or Master or BS in biological sciences, pharmaceuticals, medical sciences, or business management, finance, or related fields. Educational background in oversea as plus.

❒  Ph.D. 3+ or MS 5+ or BS 10+ years’ experience in project management in biotech or pharma industry; Familiar with biologic R&D process; Experience/knowledge in CMC development or toxicology or IND package preparation as a plus.

❒  Familiar with biotech industry policy, overseas study or working experience preferred;

❒  Excellent coordination and communication skills, multi-tasking ability and anti-pressure ability.

  Excellent teamwork skills and influence; A good team player as well as a leader in cross function environment;

  Excellent in reading and writing level both in Chinese and English


TAYU-BIOTECH Introduction:

TAYU Biotech group was established in September 2016, which is committed to develop innovative immunotherapy drug in China founded by Professor Chen Lieping who is a global famous immunologists and oncologists.

Professor Chen Lieping is the world’s leading investigator in the characterization of cell surface co-stimulatory and co-inhibitory molecules that modulate immune responses. He is professor of immunobiology, of dermatology, and of medicine (medical oncology) at Yale School of Medicine and director of the cancer immunology program at the Yale Cancer Center. Professor Chen is the first scientist to apply co-stimulation as a mean for cancer immunotherapy. His laboratory discovered immune suppressive function of the B7-H1 (PD-L1)/PD-1 pathway in cancer and first demonstrated using antibody to block this pathway to enhance tumor immunity for the therapy of cancer. The anti-PD-1 and anti-PD-L1 has been well recognized as the most safe and effective drugs for the therapy of cancer so far.

With a rich experienced R&D team, TAYU is developing anti-tumor drug including immune checkpoint inhibitors, co-stimulus antibodies, dual specificity antibodies and biomarker etc. TAYU group will strive to grow into a top biopharmaceuticals group that covers research, transformation and manufacture in the future.

For more information please click 


Contact information:

Address: 8-2 Dongdan Santiao, Dongcheng district, Beijing, China

Tel: +86 10 67177097


隐私保护 大有华夏生物医药集团有限公司 版权所有 京ICP备18005352号